This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

Inclusion Criteria:

• • Aged >= 18 years at the time of providing written informed consent.
• • Diagnosis of PMP requiring CRS with HIPEC.
• • Bleeding risk: Predicted intraoperative blood loss of >=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)

Exclusion Criteria:

• • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
• • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery.
• • Known history of chronic hepatitis.
• • Clopidogrel or ticagrelor administration within 5 days before study surgery.
• • Prasugrel administration within 7 days before study surgery.
• • Oral factor Xa inhibitor administration within 2 days before study surgery.
• • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery.
• • Oral direct thrombin inhibitor administration within 3 days before study surgery.
• • Vitamin K antagonists within 5 days before study surgery.

CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available

Proposed research should seek to answer a previously unanswered important medical or scientific question.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.